TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05393414
Drug: Opioid based protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of combination of drug dosage frequency and duration of morphine injection with percocet oral as standard postoperative pain control for up to 72 hours as requested by each patient
Study: NCT01247363
Drug: LY2608204
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00377559
Drug: Non pegylated liposomal doxorubicin and docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: max. 6 courses
Study: NCT02581397
Drug: Transpulmin syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7,5ml every 4 hours, orally, for 03 or 07 days
Study: NCT03552536
Drug: MK-8583
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of MK-8583 in capsule form
Study: NCT01752790
Drug: Top-down
Normalized name: Kool-Down Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
Study: NCT00005574
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02337283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT02245789
Drug: Propofol and remifentanil anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
Study: NCT03040635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of Risdiplam matching placebo will be administered on Day 1.
Study: NCT01991223
Drug: Dex infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
Study: NCT00361699
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00481325
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
Study: NCT00823745
Drug: [14C]-PF-00868554
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution, single dose
Study: NCT04401345
Drug: Glycopyrrolate 0.2 MG/ML
Normalized name: glycopyrrolate 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
Study: NCT04401345
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, the patients will receive 1 ml of 0.9% normal saline
Study: NCT01369082
Drug: Maintenance Immunosuppressive Treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
Study: NCT00970450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT02163720
Drug: Yondelis®-Caelyx®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation of Yondelis®-Caelyx® administration
Study: NCT02885857
Drug: Shenyan Kangfu Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
Study: NCT01188148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00800319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume matched placebo; oral solution; single dose
Study: NCT02257177
Drug: Inhaled TD139
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPI Galectin-3 inhibitor
Study: NCT02257177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPI placebo
Study: NCT00334360
Drug: Bus and Dex
Approvals — FDA: no, EMA: no, PMDA: no
Description: the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
Study: NCT04104685
Drug: 3% Minocycline Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT00715364
Drug: NTx™-265: rhCG, then rEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: * rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation
Study: NCT00715364
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation
Study: NCT01765426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline (PBS)
Study: NCT01510184
Drug: Y-90-Zevalin
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y-90-Zevalin administered by intravenous infusion.
Study: NCT01510184
Drug: In-111 Zevalin
Normalized name: In-111 Zevalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-111-Zevalin administered by intravenously.
Study: NCT02223611
Drug: S1 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)\<1.25 m2 40mg twice a day, 1.25 m2≤BSA\<1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
Study: NCT02836873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive) tablet to match the active comparator
Study: NCT04580745
Drug: MORF-057
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057.
Study: NCT04580745
Drug: Placebo for MORF-057
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo.
Study: NCT00405548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01960543
Drug: fentanyl 15 microg
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01228357
Drug: SSRI treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
Study: NCT01228357
Drug: non-SSRI treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
Study: NCT00723346
Drug: native L asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10000UI/m2, 14 infusions during 4 chemotherapy cycle
Study: NCT01479595
Drug: QBX258
Approvals — FDA: no, EMA: no, PMDA: no
Description: QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
Study: NCT01479595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
Study: NCT02255565
Drug: Very Low Dose Quillivant XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension dose once a day increasing to a 10mg dose
Study: NCT02255565
Drug: Low Dose Quillivant XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension dose once a day increasing to a 20mg dose
Study: NCT02255565
Drug: Moderate Dose Quillivant XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension dose once a day increasing to a 40mg dose
Study: NCT02496845
Drug: VL#FIA3-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive dual treatment (MH30-01 \& IS045-01)
Study: NCT02177643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules
Study: NCT02998905
Drug: Acetylsalicylic Acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 81 mg/day
Study: NCT02515045
Drug: TriMoxiVanc
Approvals — FDA: no, EMA: no, PMDA: no
Description: triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
Study: NCT02515045
Drug: Prednisolone acetate 1%
Normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
Study: NCT01429272
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg po bid for 6 weeks
Study: NCT01429272
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for minocycline and/or aspirin
Study: NCT00825396
Drug: C-KAD Ophthalmic Solution
Normalized name: urea c-13 Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 drops applied daily for 150 days
Study: NCT02156544
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01253265
Drug: LY2439821
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT01253265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT00711802
Drug: Standard of Care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02370095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
Study: NCT00900146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
Study: NCT00276094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
Study: NCT00378937
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00378937
Drug: codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00378937
Drug: dextropropoxyphene hydrochloride
Normalized name: Dextropropoxyphene hydrochloride
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02770807
Drug: Pooled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.
Study: NCT03077698
Drug: progestin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
Study: NCT00690287
Drug: AZD6370
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single doses a+b+c, o.d., suspension
Study: NCT00690287
Drug: AZD6370
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single dose, o.d., b.i.d. and q.i.d., suspension
Study: NCT00690287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04140201
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs that lower lipid level
Study: NCT02576665
Drug: Toca FC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side
Study: NCT01239888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
Study: NCT02312219
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg folic acid once daily
Study: NCT02312219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once weekly
Study: NCT02312219
Drug: Low Dose Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An anti-inflammatory drug
Study: NCT00266838
Drug: Maxidex; Lacrystat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 times daily, for 20 weeks.
Study: NCT02226198
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active drug will be taken taken orally, QD, either in the morning or in the evening
Study: NCT02226198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be taken taken orally, QD, either in the morning or in the evening
Study: NCT00437450
Drug: Epoetin/Atra
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03888677
Drug: 5-FU, epirubicin and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored dose escalation of epirubicin and cyclophosphamide.
Study: NCT02654236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
Study: NCT02654236
Drug: 10 mg Obeticholic Acid (OCA)
Normalized name: obeticholic acid 10 MG
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
Study: NCT01921218
Drug: Calcineurin inhibitor therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
Study: NCT03172065
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous flluid
Study: NCT01633203
Drug: epirubicin + cisplatin + capecitabine polychemotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~* Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~* Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~* Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea.
Study: NCT00906139
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl dose: 0.05 mg
Study: NCT00354107
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IT
Study: NCT00354107
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT00162461
Drug: Phenytoin single dose (300 mg)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02128243
Drug: S-1 de-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 30 mg/m² bid d1-14 q21d
Study: NCT02128243
Drug: Chemotherapy by Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT
Study: NCT00892203
Drug: BGG492
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00892203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03529097
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 liters of 0.9% NaCl bag covered with black bag so the participant could not tell the fluids are not dripping to his vain
Study: NCT00913809
Drug: Desipramine HCL 100 mg Tablets Cord Laboratories
Normalized name: desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00913809
Drug: Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01471418
Drug: PET/CT with 18-FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG uptake
Study: NCT01478841
Drug: polyphenol
Normalized name: Polyphenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
Study: NCT01478841
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
Study: NCT00504790
Drug: GSK923295
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-mitotic compound
Study: NCT02763475
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60mg/kg by vein on day -6
Study: NCT01611051
Drug: Drug: Pegylated rhG-CSF: 100µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
Study: NCT01611051
Drug: Pegylated rhG-CSF: 6mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
Study: NCT01611051
Drug: rhG-CSF 5ug/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
Study: NCT01156389
Drug: Pyramax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
Study: NCT01715350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks
Study: NCT00367744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for rosiglitazone
Study: NCT00819377
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml normal saline by inhalation over 15 min
Study: NCT00499655
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02257385
Drug: UMEC/VI matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
Study: NCT03035253
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.
Study: NCT03035253
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will consist of OMP-305B83 and the FOLFOX chemotherapy regimen.
Study: NCT03824275
Drug: 18F- DCFPyL PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: A CT scan using a radioactive marker to better image tumors
Study: NCT04371822
Drug: SnPP Protoporphyrin plus Sunlight exposure
Normalized name: SnPP Protoporphyrin
DrugBank: Tin protoporphyrin IX (DB16449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SnPP Protoporphyrin plus Sunlight exposure
Study: NCT04371822
Drug: SnPP Protoporphyrin plus Sunlight exposure
Normalized name: SnPP Protoporphyrin
DrugBank: Tin protoporphyrin IX (DB16449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SnPP Protoporphyrin and Sunlight exposure
Study: NCT04371822
Drug: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
Study: NCT01404013
Drug: ICS/LABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
Study: NCT01567202
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
Study: NCT01567202
Drug: blank placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline that has the same appearance with DC vaccine.
Study: NCT03835884
Drug: AR-13503 Implant 10.6 Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye
Study: NCT03835884
Drug: AR-13503 Implant 21.2 Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye